Aktuelle Publikationen
Capitalizing on the Crisis: New Ways to Create Value in Biopharma
Simon Goodall, Eric E. Olsen, Peter Tollman
9. November 2009
Faced with patent expirations, falling R&D productivity, and pricing pressures, biopharmaceutical executives are seeking new strategies to improve shareholder value. Using BCG’s proprietary methodologies, we analyze in this Focus report the total shareholder return (TSR) that would be generated under a range of different strategies. We explore a range of options including improving efficiency alone, focusing only on niche markets or high unmet need, and striving for leadership in mass markets. Our analysis and findings challenge conventional wisdom about the best way to create value in the industry. PDF ansehen
Collateral Damage Industry Focus: Implications of the Financial Crisis for the Biopharmaceutical Sector
Alastair Flanagan, Stefan Larsson, Martin B. Silverstein, M.D., Nick South
1. November 2008
The financial crisis is no longer just a financial crisis--it has spread to the wider economy. As a result, there will be what BCG has elsewhere described as significant "collateral damage." All companies will have to get used to operating in a tougher--and, in many cases, a recessionary--environment. While the overall impact may be challenging, the disruption also creates real opportunities for biopharma companies to change industry dynamics, build new sources of competitive advantage, and even tackle some of the root causes of the sector's underperformance over the last five years. Pdf ansehen
alle publikationen